EGFR and non-small cell lung carcinoma: It has been shown that the application of gefitinib and cisplatin displayed a dose-dependent antagonism in EGFR wild-type and EGFR mutant NSCLC cell lines, revealing an interference of cisplatin cell entry [30] at a concentration range of gefitinib between 0.001–0.3 μM.